Overview

Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer

Status:
Terminated
Trial end date:
2004-02-01
Target enrollment:
0
Participant gender:
All
Summary
To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Fluorouracil
Gefitinib
Leucovorin
Criteria
Inclusion Criteria:

- Histologically-confirmed intestinal GC (T2-T4)

- Local or locally advanced stage II or stage III gastric cancer of an upper part of the
stomach or GE junction

- Lymph node positive or negative

- Metastasis negative

- Resection with curative intent (R0, D2)

- Chemo- and radiotherapy naïve

- Measurable lesion according RECIST

- Written informed consent

Exclusion Criteria:

- Aged below 45 or over 70

- Prior gastric surgery

- Active ILD